CERVEAU GENESIS

In 2016, Cerveau was formed to advance MK-6240 into the mainstream of neurodegenerative disease research. Since then, MK-6240 has become an acknowledged leading imaging biomarker for Tau pathologies, central to AD progression. Cerveau licensed MK-6240 from Merck and committed to establish a broad network of production facilities to support clinical research.

Through the Cerveau Users Group, Pharma companies and leading Academic centers gain access to MK-6240 for their cutting edge research, share non-competitive data with the entire Users Group and disclose breakthrough science as appropriate.

CERVEAU EVOLUTION

Dec 2016

Merck License

Feb 2017

Siemens
PETNET
Partnership

Jun 2017

MK-6240
IND Accepted
by FDA

Jul 2017

1st Dose
Supporting
Pharma Trial

Oct 2017

MK-6240
Global
Database
Opens

Dec 2017

8 Pharma
Licenses

May 2018

471 Human
Exposures

Dec 2018

25 Trials
Initiated

May 2019

1st subject in
MK-6240
ALERT
Longitudinal
Trial

Jun 2019

1575 Human
Exposures

Oct 2019

1st Subject in
Japan Phase 1
Trial

To Date

~ 4500
Human
Exposures(12
Pharma
Licenses)

CERVEAU TEAM

This dramatic growth has been enabled by the assembly of a team of highly experienced subject matter experts covering all areas essential to the production and management of MK-6240 and its associated image data.

SCIENTIFIC ADVISORY BOARD

The internal Cerveau team is complemented by experts from across our Users Group and by an outstanding group of renowned leaders in Neurodegenerative Disease research, clinical and non-clinical.